We are excited to once again assemble many of the leading clinicians and scientists from around the world for the 7th Advances Against Aspergillosis conference, to take place in Manchester, UK from March 3-5, 2016. This 7th meeting is the 12th anniversary of the conference. This conference has now clearly established itself as the premier forum for detailed and dedicated discussion of all aspects of Aspergillus infection and research, and previously published proceedings have been very well-received. As Advances Against Aspergillosis has become the leading global meeting for basic and clinical science regarding Aspergillus, its efforts form one of the foundations of the repository of knowledge about this pathogen; 229 papers have been published in 7 Supplements, comprising 1,739 pages of full papers, as well as 1,061 abstracts from the meetings.

The Aspergillus field continues in a state of rapid advancement, including the publication of numerous post-genomic papers and substantial advances in translational, immunologic, and diagnostic research. The launch of several antifungals in the last few years and anticipated clinical trials of newer compounds is an exciting time for mycology. Itraconazole, pan-azole, and echinocandin resistance has emerged, and combination therapy following the large trial remains an important area of interest. Greatly increased awareness of allergic aspergillosis has opened new market opportunities for both antifungal agents and immunotherapies. There is a continuing high death toll from invasive aspergillosis, particularly among patient groups not usually associated with this opportunistic infection. This meeting is another chance to gather the world's aspergillosis experts in one venue. A fundamental tenet of this colloquium continues to be to engender collaborative relationships amongst clinicians, scientists, and industry to further advance the field.

The previous six international meetings were overwhelmingly successful, including the first Advances Against Aspergillosis meeting in 2004 (San Francisco) where we had 364 attendees from 28 countries, the second meeting in 2006 (Athens) with 464 attendees from 44 countries, the third meeting in 2008 (Miami) with 351 attendees from 48 countries, the fourth meeting in 2010 (Rome) with 533 attendees from 49 countries, the fifth meeting in 2012 (Istanbul) with 375 attendees from 39 countries, and the sixth meeting in 2014 (Madrid) with 342 attendees from 33 countries. The meetings were very productive for exchanging clinical and research ideas and forging new collaborations.